Postmenopausal Clinical Trial
Official title:
Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route: Pilot Study
The aim of this pilot study conducted in post-menopausal women is to evaluate the effect of 17ß-estradiol administration on inflammatory-immune cells, namely antigen-presenting cells (monocytes/dendritic cells), and more precisely on their activation by inflammatory stimuli. This study will allow us to determine our ability to recruit menopausal women and to characterize the optimal primary end-point among the numerous criteria tested
Although the beneficial effects of hormonal replacement therapy (HRT) against osteoporosis
and climacteric symptoms have been clearly established, randomized studies recently revealed
that the combined administration of oral estrogens and medroxyprogesterone acetate increases
the incidence of coronary events and strokes during the first months of treatment.
Furthermore, oral estrogens significantly enhance IL-6 and CRP secretion. This increase in
the plasma concentration of inflammatory markers probably results from a direct effect of
oral administration on the liver, since i twas not observed with estrogens administered by
transdermal route.
Our experimental data in ovariectomized mice demonstrated that the chronic subcutaneous
administration of17ß-estradiol (E2) enhances the expression of pro-inflammatory cytokines by
Th1 lymphocytes, Natural Killer T cells and monocytes/macrophages. This pro-inflammatory
effect of E2 could play a role in the deleterious vascular effects observed in randomized
studies, especially by favoring plaque instability.
Our aim is to determine whether E2 administration in menopausal women leads to an
inflammatory phenotype of circulating antigen-presenting cells, especially monocytes.
Indeed, evaluating the inflammatory status at the cellular level probably gives more precise
informations than plasma cytokine concentrations to predict the ability of estrogens to
enhance inflammatory processes. We first propose a pilot study in order to determine
enrollment feasibility, as well as the optimal biological endpoints to assess monocyte
activation status. These latter criteria will be then used in a future randomized study
comparing two routes of E2 administration (oral vs transdermal).
The present study will include 34 menopausal women. After the inclusion visit, three visits
will be performed with the collection of a 50 ml blood sample and the isolation of
circulating immune cells (monocytes).
The following criteria will be studied before (V1 and V2) and after 30 ± 3 days of E2
treatment (V3:
1. expression of surface activation molecules.
2. Secretion of cytokines in response to several Toll-like receptor stimuli.
3. IL-6 and CRP-US plasma concentrations.
We will first assess the intra-individual variability (V1 and V2). At visit 2 (V2), the
subjects will be randomized to receive E2 either by oral (n= 17) or transdermal (n= 17)
route.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02235051 -
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
|
N/A | |
Completed |
NCT01635413 -
Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)
|
N/A | |
Recruiting |
NCT04705623 -
Influence of Iyengar Yoga on the Bio-functional Age of Postmenopausal Women
|
N/A | |
Withdrawn |
NCT03238703 -
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
|
Phase 4 | |
Completed |
NCT03756272 -
Stellate Ganglion Block to Reduce Hot Flushes
|
N/A | |
Recruiting |
NCT03953157 -
Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors
|
N/A | |
Completed |
NCT00338728 -
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT01482702 -
Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors
|
N/A | |
Not yet recruiting |
NCT05009238 -
Effect of l S Exercises on Balance and Spatiotemporal Gait Parameters in P M Women
|
N/A | |
Terminated |
NCT01842217 -
Validation of [18F]FES for Imaging of Brain Estrogen Receptors
|
N/A | |
Completed |
NCT01172574 -
Motor Control Exercise in Osteoporotic Women
|
N/A | |
Completed |
NCT00530582 -
Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women
|
Phase 4 | |
Completed |
NCT01825785 -
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)
|
Phase 1 | |
Completed |
NCT04364061 -
Post Exercise Substrate Oxidation, Appetite and Energy Intakes in Overweight/Obese Postmenopausal Women (EScAPE)
|
N/A | |
Completed |
NCT03180294 -
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
|
Phase 2 | |
Recruiting |
NCT06445842 -
Short-term Circuit Training on Muscle Mass and Quality of Life in Sedentary Postmenopausal Women
|
N/A | |
Completed |
NCT01753908 -
Broccoli Sprout Extract in Treating Patients With Breast Cancer
|
Early Phase 1 | |
Not yet recruiting |
NCT06377631 -
Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity
|
N/A | |
Recruiting |
NCT06228768 -
Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer
|
N/A | |
Terminated |
NCT01294397 -
Effects of Denosumab on the Pharmacokinetics of Etanercept
|
Phase 1 |